AXIM BIOTECHNOLOGIES, INC. Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss
AXIM BIOTECHNOLOGIES, INC. (AXIM) reported Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss of -$104.70 thousand for the 3-month period ending 2020-03-31, per its 10-Q/A filed 2020-07-02.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2020-07-02
- AXIM BIOTECHNOLOGIES, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2020-03-31 was -$104.70K, a 518.82% decline year-over-year.
- AXIM BIOTECHNOLOGIES, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2019-03-31 was $25.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month |
|---|---|---|
| 2020-03-31 | -$104.70K 10-Q/A · filed 2020-07-02 | |
| 2019-09-30 | $273.72K 10-Q · filed 2019-11-14 | |
| 2019-03-31 | $25.00K 10-Q/A · filed 2020-07-02 | |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-14 |